trending Market Intelligence /marketintelligence/en/news-insights/trending/dpiFXcMQ6obgiYvDeIPF0w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Gritstone drug gets US FDA fast-track designation for bowel cancer

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Gritstone drug gets US FDA fast-track designation for bowel cancer

Gritstone Oncology Inc. said the U.S. Food and Drug Administration granted fast-track designation for its Granite-001 for treating bowel cancer.

Granite-001 — the company's lead product candidate — is a personalized treatment that enables the immune system to fight cancer and is developed using Gritstone's proprietary Edge artificial intelligence platform.

The Emeryville, Calif.-based biotechnology company is evaluating the drug in a phase 1/2 trial with patients having common solid tumors.

The fast-track designation will qualify Gritstone to meet and communicate more frequently with the FDA during the development of Granite-001. It will also allow for the accelerated approval and priority review of the drug's application.

Gritstone develops tumor-specific cancer treatments for multiple types of the disease by leveraging the immune system to recognize and destroy tumor cells.